Vaxxinity Receivables

The latest receivables for VAXX is $410K as of December 2023. That compares with $410K in the prior-year period — up 0.0% year over year. Investors often review this figure alongside Vaxxinity's historical trend and sector peers before judging valuation or financial health.

Over the past year, VAXX's receivables moved from $410K to $410K — essentially flat versus a year earlier. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vaxxinity's operating scale or balance-sheet position.

A receivables figure of $410K for VAXX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting VAXX's receivables ($410K), review year-over-year change from $410K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.